Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2020
Event: Entry into a Material Definitive Agreement with Innovent Biologics (Suzhou) Co., Ltd.
Key Financial Metrics and Transaction Terms
This filing details a strategic license agreement rather than periodic financial results. Key financial terms include:
- Upfront Payment: $5,000,000 payable to Innovent.
- Milestone Payments (Bevacizumab): Up to $40,000,000 contingent on development, regulatory, and sales milestones.
- Milestone Payments (Rituximab Option): Up to $40,000,000 if the option is exercised.
- Option Exercise Fee: $5,000,000 required to exercise the rituximab option.
- Technology Transfer Fees: Up to $10,000,000 if the Company requests Innovent to perform technology transfer.
- Royalties: Mid-teens to low twenty percent of net sales of Licensed Products.
Material Changes and Strategic Developments
The Company entered into an exclusive, royalty-bearing license to develop and commercialize a biosimilar version of bevacizumab (Avastin) in the United States and Canada. Additionally, the Company acquired an option to license a biosimilar version of rituximab (Rituxan) in the same territory. The agreement includes provisions for Innovent to supply products and perform technology transfer, after which Coherus would hold exclusive manufacturing rights in the Territory.
Outlook, Risks, and Contingencies
- Term: Initial term of 10 years for bevacizumab, renewable for successive 2-year periods. The rituximab term would similarly be 10 years from the option effective date.
- Termination Rights: Either party may terminate for material breach or bankruptcy. Innovent may terminate upon a change of control involving a competitor. Coherus may terminate based on market conditions 12 months after first commercial sale or due to regulatory delays/adverse FDA feedback.
- Regulatory Risk: The agreement allows for termination if the FDA recommends an additional phase 3 clinical trial efficacy comparability study.
- Financial Impact: The filing does not provide current revenue, profit, cash flow, or debt metrics. The financial impact is contingent on future milestone achievements and sales.
Investor Verification Checklist
- Verify the Company's current cash position to assess the ability to fund the $5 million upfront payment and potential future milestones.
- Review the full text of the License Agreement (to be filed as an exhibit to the 2019 Form 10-K) for detailed definitions of milestones and termination clauses.
- Monitor the status of the rituximab option exercise window (12 months from receipt of regulatory materials).
- Assess the competitive landscape for bevacizumab and rituximab biosimilars in the U.S. and Canada.
- Track FDA regulatory feedback regarding the bevacizumab biosimilar to evaluate termination risks related to clinical trial requirements.